Lessons From Bluebird Bio: How To Launch Advanced Therapies in Germany
Outcomes-based deals are important for launching cell and gene therapies in Germany, but bluebird bio’s painful experience with Zynteglo shows the importance of the taking the right approach to ensure market success.
You may also be interested in...
The head of Novartis Gene Therapies in Europe tells Scrip that innovative payment models and involving all stakeholders have helped payers see beyond a simple price tag and see the benefits of a one-time gene therapy for spinal muscular atrophy.
If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.
Transparency on pricing and cost calculations could improve and inform public policy on medicines access, say EU health ministers.